TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23611363
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment and care
Study: 19931345
Drug: Mandibular-implant overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular-implant overdentures
Study: 12214785
Drug: Cognitive-behavioural programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural programme with 5-8 weekly home-visits
Study: 7920454
Drug: Carbenoxolone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (300 mg/day for 5 days) in normal subjects
Study: 7920454
Drug: Carbenoxolone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (300 mg/day for 5 days) in patients with renal disease
Study: 2838979
Drug: Propranolol (75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (75-100 mg/d)
Study: 19502478
Drug: Parent Skills
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent Skills with Behavioral Couples Therapy (PSBCT)
Study: 7518763
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 10 mg/kg twice daily for 10 days
Study: 7518763
Drug: Cefaclor 10
Normalized name: cefaclor 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 10 mg/kg twice daily for 10 days
Study: 28288601
Drug: Multimodal behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal behavioral intervention (MBI) treatment including telephone counseling, nicotine replacement therapy, mobile app support, multimedia text messages about TSE and smoking cessation.
Study: 24837362
Drug: CE/BZA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/BZA (both doses)
Study: 24837362
Drug: CE/BZA (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/BZA (higher dose)
Study: 2572181
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine applied twice daily
Study: 1086728
Drug: Schwarz live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz live, further attenuated measles virus vaccine at full dose (0.5 ml)
Study: 1086728
Drug: Schwarz live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz live, further attenuated measles virus vaccine at reduced doses (40%, 60%, or 80%)
Study: 1086728
Drug: Schwarz live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz live, further attenuated measles virus vaccine at reduced volume below 0.5 ml
Study: 1086728
Drug: Schwarz live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz live, further attenuated measles virus vaccine in children below 12 months of age
Study: 21985174
Drug: Baseline imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline imaging after completion of 5-7 months of anticoagulant therapy
Study: 21985174
Drug: No baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: No baseline imaging after completion of 5-7 months of anticoagulant therapy
Study: 27657899
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation
Study: 15630988
Drug: Combination treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatments with newer chemotherapy agents and optimal radiotherapy protocols
Study: 15630988
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment strategies
Study: 9160851
Drug: Nicotine-containing cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-containing cigarettes (0.1 mg per puff)
Study: 9160851
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (0.5 mg nicotine per spray)
Study: 9160851
Drug: Vapor inhaler
Normalized name: Vapor Inhaler
DrugBank: Levmetamfetamine (DB09571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vapor inhaler (estimated 0.013 mg nicotine per inhalation)
Study: 9160851
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 puffs, sprays, or inhalations)
Study: 8226172
Drug: Radiation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation and simultaneous daily cisplatin
Study: 8226172
Drug: Cisplatin containing
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin containing combination regimens with thoracic radiation
Study: 8226172
Drug: Thoracic radiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiation therapy with or without single agent cisplatin
Study: 8226172
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation and concurrent cisplatin containing combination therapies
Study: 8226172
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy and surgery
Study: 3780826
Drug: SUR2647 combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUR2647 combination (2 g paracetamol X 2 on the day of operation, 1 g paracetamol X 2 on the following two days)
Study: 3780826
Drug: SUR2647 combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUR2647 combination
Study: 29383893
Drug: Tiaoshen Kaiyu
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaoshen Kaiyu acupuncture plus standard treatment and psychological intervention
Study: 29383893
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus psychological intervention (control group)
Study: 8544547
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (up to 120 mg daily)
Study: 8544547
Drug: Benztropine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine (active placebo, up to 1 mg twice daily)
Study: 1860151
Drug: Rice-based oral
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based oral rehydration therapy (ORT)
Study: 1860151
Drug: Sugar-based oral
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-based oral rehydration therapy (ORT)
Study: 30576555
Drug: Methylprednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (60 mg/d)
Study: 30576555
Drug: Ketoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200 mg/d)
Study: 25112302
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous saline solution)
Study: 11285552
Drug: Immediate postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postoperative radiation therapy (RT)
Study: 11285552
Drug: Delayed radiation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed radiation therapy (RT)
Study: 11285552
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (approximately 45-50 Gray (Gy))
Study: 11285552
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (approximately 60-65 Gy)
Study: 8179231
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of terfenadine twice daily for 1 week
Study: 8179231
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 1 week
Study: 2885946
Drug: Hemodilution (graded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution (graded venesection 250‐1000 ml during the first 2 days and dextran 40 infusions 500 ml daily for 5 days)
Study: 30324496
Drug: Snapcare app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Snapcare app (App group) in addition to a written prescription
Study: 30324496
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Conventional group) with a written prescription
Study: 25437716
Drug: Transcervical intralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical intralesional vasopressin injection
Study: 20334708
Drug: Pomegranate seed
Normalized name: pomegranate seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate seed oil (PSO) 400 mg twice daily
Study: 18773990
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (E-Alone)
Study: 18773990
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (E+P)
Study: 15904514
Drug: Typhoid Vi
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi polysaccharide vaccine
Study: 7573074
Drug: Randomly assigned
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomly assigned intensity of exposure (0.1-40 fibers/ml)
Study: 2099961
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and oral Pentoxifylline
Study: 7007058
Drug: Methenamine hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine hippurate (MH), 1 g three times daily
Study: 7007058
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 g three times daily
Study: 23190780
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hepatitis B vaccine)
Study: 8950498
Drug: Inogatran (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (low molecular weight thrombin inhibitor)
Study: 2031078
Drug: Recombinant alpha
Normalized name: Recombinant alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha 2b-interferon alone (6 weeks of placebo syrup followed by 16 weeks of recombinant alpha 2b-interferon, 5 x 10(6) u/m2 subcutaneously thrice weekly)
Study: 2031078
Drug: Recombinant alpha
Normalized name: Recombinant alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha 2b-interferon with steroid priming (6 weeks of syrup prednisone followed by 16 weeks of recombinant alpha 2b-interferon)
Study: 2031078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (syrup vitamin B complex)
Study: 31551223
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Zushima tablet and western medicine
Study: 18590256
Drug: Partial removal
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial removal with water spray cooled drills
Study: 16091427
Drug: Non-study patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-study patients treated with chemotherapy
Study: 11815986
Drug: Sandwich chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich chemotherapy (ifosfamide, etoposide, methotrexate, cisplatin, and cytosine arabinoside) followed by irradiation
Study: 11815986
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (lomustine, vincristine, and cisplatin) followed by irradiation
Study: 10881087
Drug: Mefloquine, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine, 250 mg per day in a single dose for six days, repeated three weeks later.
Study: 10881087
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (Glucantime), 20 mg/kg daily administered intravenously for 20 days.
Study: 1799037
Drug: Triiodinated agents
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triiodinated agents
Study: 29925490
Drug: Bictegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir alafenamide (25 mg)
Study: 29925490
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor regimen
Study: 29925490
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor group
Study: 17149725
Drug: NS 2330
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NS 2330 (tesofensine) 0.25 mg
Study: 17149725
Drug: NS 2330
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NS 2330 (tesofensine) 0.5 mg
Study: 17149725
Drug: NS 2330
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NS 2330 (tesofensine) 1.0 mg
Study: 24326799
Drug: Intravenous Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Oxytocin
Study: 9803773
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of Ginkgo biloba extract (EGb)
Study: 9803773
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of tacrine
Study: 7652633
Drug: Meclofenamate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate (100 mg 3 times a day)
Study: 7652633
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg 3 times a day)
Study: 2523646
Drug: Isradipine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5, 5, 7.5, or 10 mg twice daily)
Study: 2523646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isradipine and atenolol
Study: 1064902
Drug: Rapidly-disintegrating ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapidly-disintegrating ferrous sulphate tablets
Study: 1064902
Drug: Ferrous carbonate
Normalized name: ferrous carbonate
DrugBank: Ferrous carbonate (DB13698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous carbonate tablets
Study: 1064902
Drug: Slow-release ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release ferrous sulphate tablets
Study: 1064902
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate solution (reference)
Study: 26917439
Drug: 6-mm implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm implants (test group)
Study: 26917439
Drug: 10-mm implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mm implants (control group)
Study: 22569050
Drug: Postoperative nasal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative nasal spray regimens (specific regimens not detailed)
Study: 22569050
Drug: Age, gender,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, gender, and nasal spray regimen
Study: 20439954
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment of malaria in infants (IPTi) with sulphadoxine‐pyrimethamine
Study: 30027912
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5% solution plus low-level light therapy twice per day
Study: 30027912
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5% solution with a laser comb system turned off (placebo)
Study: 30027912
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5% solution plus low-level light therapy
Study: 26468161
Drug: Vehicle (l-arginine)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (l-arginine)
Study: 16088848
Drug: Candesartan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (16 mg, increased to 32 mg after one month)
Study: 9745827
Drug: Baerveldt glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt glaucoma implant
Study: 3311145
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of viscous polysaccharides or 'slow-release' carbohydrates
Study: 29652929
Drug: MVA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA vaccine (Groups 1-3)
Study: 25613811
Drug: Latanoprost-timolol fixed
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost-timolol fixed combination (LTFC)
Study: 21906390
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (HFCWO)
Study: 16702890
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (37.5-300 mg/d)
Study: 14692709
Drug: Liverman capsule
Normalized name: Ivermax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liverman capsule
Study: 14692709
Drug: Legalon capsule
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legalon capsule
Study: 14692709
Drug: Silymarin tablet
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin tablet
Study: 8922657
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triiodothyronine (T3) 20 micrograms three times daily for 7 days
Study: 23391367
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of arbidol (0.2 g, 0.4 g, 0.8 g)
Study: 23391367
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of arbidol (0.2 g, 3 times a day for 7 days)
Study: 12841306
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin C and E
Study: 9732305
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (7000 microg retinol equivalents weekly)
Study: 9732305
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (7000 microg retinol equivalents weekly)
Study: 7666265
Drug: Heparin intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin intake (mean 83.5 units/kg/day)
Study: 7666265
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin intake (mean 59.4 units/kg/day)
Study: 2773833
Drug: Moderate nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate nicotine dose (15 micrograms/kg body wt)
Study: 2773833
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine dose (7.5 micrograms/kg body wt)
Study: 61951
Drug: Benetazone Spofa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benetazone Spofa (trimethazone) 1000 mg/day
Study: 61951
Drug: Phenylbutazone 600
Normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone 600 mg/day
Study: 26905330
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by radical surgery (NACT-RS)
Study: 24984991
Drug: Combined calcium
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined calcium and iron (700 mg Ca as calcium carbonate plus 30 mg Fe as ferrous sulfate)
Study: 24984991
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation alone (30 mg Fe as ferrous sulfate)
Study: 19950575
Drug: PAS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAS group (aspirin 100 mg, atorvastatin 10 mg, probucol 0.25 g daily)
Study: 19950575
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (aspirin 100 mg, atorvastatin 10 mg daily)
Study: 14692903
Drug: PGB, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB, 150 mg/day
Study: 14692903
Drug: PGB, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB, 600 mg/day
Study: 11208823
Drug: 12 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12 monthly cycles of adjuvant CMF chemotherapy
Study: 7877646
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after radical mastectomy
Study: 8092756
Drug: Buflomedil infusion
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil infusion
Study: 28633777
Drug: Superficial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial corticosteroid injection
Study: 28633777
Drug: Deep corticosteroid
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep corticosteroid injection
Study: 17291932
Drug: Intravenous diuretics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diuretics
Study: 9925061
Drug: n of
Normalized name: Antigen of mold
Approvals — FDA: no, EMA: no, PMDA: no
Description: n of 1 trials (theophylline therapy)
Study: 9925061
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice (theophylline therapy)